MARKET

CSBR

CSBR

Champions
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.46
-0.23
-1.97%
After Hours: 11.46 0 0.00% 16:00 02/25 EST
OPEN
11.60
PREV CLOSE
11.69
HIGH
11.79
LOW
11.21
VOLUME
13.02K
TURNOVER
--
52 WEEK HIGH
13.45
52 WEEK LOW
4.020
MARKET CAP
153.21M
P/E (TTM)
-88.2897
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Champions Oncology Announces Addition to Board of Directors
HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to annou...
ACCESSWIRE · 3d ago
Humanized Mouse Model Market Growth 2021 CAGR Value, Analysis by Size, Share, Top Key Players, Latest Trends and Forecast to 2024
Feb 18, 2021 (The Expresswire) -- “Humanized Mouse Model Market” report provides key statistics on the market status of the Humanized Mouse Model...
The Express Wire · 02/18 08:13
8-K: CHAMPIONS ONCOLOGY, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/13 02:20
COVID-19 Business Impact: Patient Derived Xenograft PDX Models Market Hierarchy of Needs -Moving from Pandemic Risk Management to Organizational Agility During 2025
AmericaNewsHour · 02/10 14:31
Humanized Mouse Model Market Terms and Agreements 2021-2025: Deal Trends, Players and Financials
Feb 10, 2021 (AmericaNewsHour) -- The global Humanized Mouse Model Market was valued at USD 73.21 million in 2016 and is projected to reach USD 166.24...
AmericaNewsHour · 02/10 11:32
Global Patient Derived Xenograft Models Market 2020 with COVID-19 After Effects - Growth Drivers, Top Key Players, Industry Segments and Forecast to 2025
Feb 03, 2021 (CDN Newswire via Comtex) -- Global Patient Derived Xenograft Models Market 2020 by Manufacturers, Regions, Type and Application, Forecast to...
CDN Newswire · 02/03 19:02
Global Patient Derived Xenograft Models Market 2020 Ecosystem Player Profiles, Value Chain and Industry Strategies to 2025
Feb 01, 2021 (CDN Newswire via Comtex) -- Global Patient Derived Xenograft Models Market 2020 by Manufacturers, Type and Application, Forecast to 2025...
CDN Newswire · 02/02 04:23
Can You Imagine How Jubilant Champions Oncology's (NASDAQ:CSBR) Shareholders Feel About Its 220% Share Price Gain?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Simply Wall St. · 01/29 05:24
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CSBR. Analyze the recent business situations of Champions through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CSBR stock price target is 13.83 with a high estimate of 14.00 and a low estimate of 13.50.
EPS
Institutional Holdings
Institutions: 72
Institutional Holdings: 10.08M
% Owned: 75.41%
Shares Outstanding: 13.37M
TypeInstitutionsShares
Increased
12
121.24K
New
9
2.73M
Decreased
19
340.40K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Director
Joel Ackerman
Chief Executive Officer/Director
Ronnie Morris
Chief Financial Officer
David Miller
Lead Director/Independent Director
David Sidransky
Director
Robert Brainin
Independent Director
Philip Breitfeld
Independent Director
Daniel Mendelson
Independent Director
Scott Tobin
  • Dividends
  • Splits
  • Insider Activity
No Data
About CSBR
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.

Webull offers kinds of Champions Oncology Inc stock information, including NASDAQ:CSBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSBR stock methods without spending real money on the virtual paper trading platform.